Eckstein M - Search Results

1

The outcome of patients with inflammatory bowel disease-associated colorectal cancer is not worse than that of patients with sporadic colorectal cancer-a matched-pair analysis of survival.

Vitali F, Wein A, Rath T, Eckstein M, Neufert C, Siebler J, Atreya R, Hartmann A, Hohenberger W, Weber K, Neurath MF, Grützmann R, Merkel S. Vitali F, et al. Among authors: eckstein m. Int J Colorectal Dis. 2022 Feb;37(2):381-391. doi: 10.1007/s00384-021-04072-9. Epub 2021 Dec 4. Int J Colorectal Dis. 2022. PMID: 34865179 Free PMC article.

2

In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.

Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium. Breyer J, et al. Among authors: eckstein m. Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10. Virchows Arch. 2017. PMID: 28074276

3

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W. Sikic D, et al. Among authors: eckstein m. Transl Oncol. 2017 Jun;10(3):340-345. doi: 10.1016/j.tranon.2017.01.013. Epub 2017 Mar 22. Transl Oncol. 2017. PMID: 28342317 Free PMC article.

4

FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.

Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P. Rinaldetti S, et al. Among authors: eckstein m. Oncotarget. 2017 Jul 18;8(29):47595-47606. doi: 10.18632/oncotarget.17394. Oncotarget. 2017. PMID: 28498805 Free PMC article.

5

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.

Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A. Breyer J, et al. Among authors: eckstein m. Cancer Immunol Immunother. 2018 Mar;67(3):403-412. doi: 10.1007/s00262-017-2093-9. Epub 2017 Nov 17. Cancer Immunol Immunother. 2018. PMID: 29150702 Free PMC article.

6

Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.

Otto W, van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A. Otto W, et al. Among authors: eckstein m. Int J Urol. 2018 May;25(5):442-449. doi: 10.1111/iju.13532. Epub 2018 Feb 22. Int J Urol. 2018. PMID: 29473226

7

DICER1 mutation-positive giant botryoid fibroepithelial polyp of the urinary bladder mimicking embryonal rhabdomyosarcoma.

Eckstein M, Agaimy A, Woenckhaus J, Winter A, Bittmann I, Janzen J, Bertz S, Haller F, Hartmann A. Eckstein M, et al. Hum Pathol. 2019 Feb;84:1-7. doi: 10.1016/j.humpath.2018.05.015. Epub 2018 Jun 5. Hum Pathol. 2019. PMID: 29883781

8

Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening.

Rinaldetti S, Rempel E, Worst TS, Eckstein M, Steidler A, Weiss CA, Bolenz C, Hartmann A, Erben P. Rinaldetti S, et al. Among authors: eckstein m. Oncotarget. 2018 May 25;9(40):25935-25945. doi: 10.18632/oncotarget.25407. eCollection 2018 May 25. Oncotarget. 2018. PMID: 29899832 Free PMC article.

9

FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.

Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R, Eckstein M, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W. Breyer J, et al. Among authors: eckstein m. BJU Int. 2019 Jan;123(1):187-196. doi: 10.1111/bju.14525. Epub 2018 Sep 9. BJU Int. 2019. PMID: 30120861

10

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P. Worst TS, et al. Among authors: eckstein m. Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x. Sci Rep. 2018. PMID: 30258198 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

742 results

Search Page

Filters